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Sustained stimulation of platelets with protease-activated receptor agonists in presence of extracellular calcium was associated with tyrosine
dephosphorylation of specific proteins of relative mobilities 35, 67, and 75 kDa. From phosphatase assays and inhibitor studies SHP1, a Src
homology 2 (SH2) domain-containing tyrosine phosphatase expressed abundantly in hemopoietic cells, was found to be upregulated in platelets
between 25 and 30 min following thrombin stimulation. Concomitantly, SHP1 was tyrosine phosphorylated by, and coprecipitated with, Src
tyrosine kinase. SHP1 activation, association with Src and dephosphorylation of specific proteins were dependent on extracellular calcium and
maintenance of a higher cytosolic calcium plateau. There was progressive impairment of platelet functions like aggregability and clot retraction,
associated with downregulation of fibrinogen-binding affinity of integrin αIIbβ3, in the platelets exposed to thrombin for 45 min. This could reflect
the late physiological changes in platelets when the cells are consistently exposed to stimulatory signals under thrombogenic environment in vivo.
© 2006 Elsevier B.V. All rights reserved.Keywords: Platelet activation; Intracellular calcium; Protein tyrosine phosphatase; Src tyrosine kinase; SHP1; Thrombin1. Introduction
Under a thrombogenic environment platelets exhibit a range
of hemostatic responses in vivo, including adherence to exposed
endothelium, formation of cell–cell aggregates, release of
stimulatory molecules from the intracellular stores and assembly
of prothrombinase complex on surface membrane leading to
generation of thrombin. Aggregated platelets remain embedded
in a meshwork of fibrin plugging the site of injury. Platelets
remaining free in the immediate vicinity are consistently ex-
posed to the high titer of agonists in the microenvironment, getAbbreviations: PTP, protein tyrosine phosphatase; PAR, protease-activated
receptor; pNPP, para-nitrophenyl phosphate; FITC, fluorescein isothiocyanate;
DMSO, dimethylsulphoxide; SH2, Src homology domain 2; BAPTA-AM, 1,2-
bis(2-aminophenoxy)-ethane-N,N,N′,N′-tetraacetic acid tetrakis(acetoxymethyl
ester); [Ca2+]i, intracellular-free calcium concentration
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bus. Presence of calcium in the extracellular milieu is a strong
determinant in favor of thrombus formation and contributes to
this ongoing cycle. Although platelet aggregation serves an
important role in the control of hemorrhage, uncontrolled growth
of thrombus leads to the pathological state [1]. Indeed, nature has
provided several physiological ‘checks’ to contain the process,
which include generation of NO and prostacyclins by the
endothelium [2], inbuilt pathways for removal of thrombin,
fibrin and platelets from the lesion site and other ill understood
mechanisms.
Platelet activation is associated with temporal waves of
protein tyrosine phosphorylation induced by the members of Src
family kinases, Syk and focal adhesion kinase [3]. Under resting
condition, the level of tyrosine phosphorylated proteins remains
low in the platelets, suggestive of the existence of basal
phosphatase activity [4]. 1PTPs identified in platelets include
PTP1B, Src homology 2 (SH2)-domain containing tyrosine
phosphatases 1 and 2 (SHP1 and SHP2) and PTPH1 [4–6], out
of which SHP1 is predominantly expressed in the hemopoietic
cell lines. SHP1 contains tandem SH2 domains within the N-
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proteins including Src [7–9]. Enzymatic activity of SHP1 is
upregulated by phosphorylation of its tyrosine residues [8,10], or
its proteolytic cleavage by the calcium-dependent protease,
calpain [11,12]. On the contrary, phosphorylation on Ser591 at its
C-terminus by protein kinase Cα leads to inhibition of the
phosphatase activity [13]. SHP1 is known to translocate to the
cytoskeleton in activated platelets [14] and associate with the
membrane protein PECAM1 (CD31) [15,16] and adaptor pro-
tein Grb2 [17]. Tyrosine phosphatases are implicated in different
platelet functions like regulation of calcium influx [18], clot
retraction [19], microvesicle shedding [11] and post-aggregatory
signaling [20,21]. Indeed, a balance between tyrosine kinase and
phosphatase activities is essential for platelet function.
Studies on platelet activation have mostly focused on the
early signaling events in agonist-stimulated cells. However, in
physiological milieu platelets remain continuously exposed to
thrombin for a prolonged period at the site of thrombus. Thus,
the aim in this paper was to investigate the effects of sustained
thrombin exposure on the platelets.2. Experimental procedures
2.1. Antibodies and chemicals
Monoclonal anti-phosphotyrosine IgG2b (clone PY99) and polyclonal
antibody against SHP1 (sc-287) were purchased from Santa Cruz, USA.
Fluorescein isothiocyanate (FITC)-labeled PAC1 and annexin V were from
Becton Dickinson (USA). The horseradish peroxidase-labeled secondary
antibodies were purchased from Bangalore Genei, India. BAPTA/AM (196419),
PP1, PP3 and protein tyrosine phosphatase inhibitor-1 (α-Bromo-4-hydroxyace-
tophenone) (540200), a specific inhibitor for SHP-1 and PTP1B, were from
Calbiochem, USA. Human thrombin, apyrase (grade III) (A 7646), EGTA,
acetylsalicylic acid, bovine serum albumin (fraction V), HEPES, phenylarsine
oxide (P-1646), sodium orthovanadate (S-6508), protein A–sepharose, Nonidet
P-40, the protease inhibitors, dimethylsulphoxide, paraformaldehyde and p-
nitrophenylphosphate were from Sigma, USA. Tween 20 was from Bio-Rad
(USA). The Super Signal West Pico chemiluminescent substrate was from Pierce
(USA). The reagents for electrophoresis were either from SRL (India) or
Spectrochem (India). Fura-2 AM and anti-Src mAb (MAP 327) were kind gifts
from Dr. Peter Presek (Martin-Luther-Universtät, Halle-Wittenberg). All other
reagents were of analytical grade.
2.2. Platelet activation and aggregation
Platelets were isolated by differential centrifugation from fresh human blood
donated by healthy volunteers, as already described [20,21]. The final cell count
was adjusted to 0.8–1.2×10 9/ml. Platelets were stimulated with thrombin (1 U/
ml) for 45 min at 37 °C in the absence of stirring in a Chrono-log platelet ionized
calcium aggregometer (model 600). In some experiments, platelets were
incubated with 2 mM Ca2+ for 90 s prior to addition of thrombin. Whenever
indicated, EGTA (4 mM) was added simultaneously with thrombin. In other
experiments, platelets were incubated at 37 °C with either PAO (2 μM), sodium
orthovanadate (7.5 mM) or protein tyrosine phosphatase inhibitor-1 (50 μM) for
5 min each, or with BAPTA-AM (50 μM) for 20 min, prior to the addition of
thrombin. Control platelets were incubated with respective vehicles at
concentrations similar to the reagents; volume of DMSO did not exceed 0.5%
of total volume in any of the experiments. Whenever required, aggregation was
induced by stirring (1200 rpm) and measured from the change of light
transmission. For analysis of protein phosphorylation, platelets were transferred
to one-fourth volume of 5× sample buffer, supplemented with EGTA (5 mM),
EDTA (5 mM), sodium orthovanadate (1 mM), and proteins were solubilized by
boiling at 95 °C for 5 min.2.3. Fibrin clot retraction
Clot retraction studies were carried out as described previously [22] with
somemodifications. Briefly, platelets were stimulatedwith thrombin for different
time points and transferred into glass tubes containing equal volumes of
autologous plasma. Fibrin clots were formed within a few minutes, which
retracted progressively at 37 °C. After 1 h, the clots were carefully removed and
the extent of retraction was determined from percent increase in the residual
plasma volumes. Control experiments were carried out without platelets.
2.4. Measurement of intracellular calcium
PRPwas incubatedwith 2 μMFura 2-AM for 45min at 37 °C in the dark. The
Fura 2-loaded platelets were washed and resuspended in buffer B at 108 cells/ml.
Fluorescence was recorded in 400 μl aliquots of platelet suspension at 37 °C
under non-stirring condition in a Hitachi fluorescence spectrophotometer (model
F-2500). Excitation wavelengths were 340 and 380 nm and emission wavelength
was set at 510 nm. Changes in intracellular free calcium concentration, [Ca2+]i,
were monitored from the fluorescence ratio (340/380) using FL Solutions soft-
ware. Fluorescence ratio was acquired continuously for 2 min and light path
was blocked thereafter by closing the shutter in instrument to avoid photo-
bleaching of the fluorochrome. [Ca2+]i was measured subsequently in the same
samples after 30- and 45-min intervals. Intracellular free calcium was calibrated
according to the derivation of Grynkiewicz et al. [23].
2.5. Platelet tyrosine phosphatase assay
Assay for total platelet tyrosine phosphatase was carried out as described
previously [24]. Briefly, platelets were lysed with 0.5 vol of 3× lysis buffer (3%
NP-40, 150 mM Tris–HCl, pH 7.4, 450 mM NaCl, 3 mM PMSF, 15 μg/ml
leupeptin and 15 μg/ml aprotinin) for 30 min at 4 °C. PTP activity was measured
in 200 μl aliquots of platelet lysates incubated with equal vol of the reaction
mixture (HEPES, 62 mM, pH 7.5 and p-nitrophenylphosphate, 8 mM) at 37 °C.
Appearance of the cleaved product was monitored at 405 nm in a spectrophoto-
meter (Pharmacia, model Ultrospec 1000E). Duplicates were performed in the
presence of pervanadate (1 mM) to ensure that the measured phosphatase activity
was due to tyrosine phosphatase. To determine the contribution of SHP-1,
platelets were preincubated with protein tyrosine phosphatase inhibitor-1
(50 μM) for 5 min. In some experiments in vitro phosphatase assay was carried
out on the immunoprecipitated SHP1 (see below).
2.6. Immunoprecipitation
Five hundred microliters platelet suspension (equivalent to about 1 mg
platelet proteins) was lysed in equal volume of 2× radioimmunoprecipitation
assay (RIPA) buffer (pH 7.4, 2% Triton X-100, 2 mM EGTA, 2 mM EDTA,
100 mM HEPES, 150 mM NaCl, 2 mM Na3VO4, 21 μM leupeptin, 2 mM
phenylmethylsulfonyl fluoride, 20 μM pepstatin A and 0.56 trypsin inhibitor
unit/ml aprotinin) on ice. The lysate was clarified by centrifugation at 16,000×g
for 15 min at 4 °C. The supernatant was precleared with rabbit IgG and protein
A–sepharose, followed by incubation with 2 μg anti-SHP1 antibody and protein
A–sepharose together for 2 h. The immunoprecipitates were pelleted by
centrifugation for 5 min at 16,000×g and washed thrice in 1× RIPA buffer
(without protease inhibitors). Immune complexes were finally solubilized in
35 μl of 2× sample buffer.
2.7. Immunoblotting studies
Equal amounts of platelet proteins (80–100 μg) were resolved on 10% SDS-
PAGE gels and electrophoretically transferred to Immobilon-P PVDF mem-
branes (Millipore) by using NovaBlot semidry system (Amersham Biosciences)
as per manufacture's instructions. The membranes were blocked with 10%
bovine serum albumin in 10 mM Tris–HCl, 150 mM NaCl, pH 8.0 (TBS)
containing 0.05% Tween 20 for 2 h at room temperature. The blots were then
incubated for 2 h with different dilutions of primary antibodies as follows: anti
phosphotyrosine mAb, 1:1000; anti-Src mAb, 1:500, and rabbit anti-SHP1,
1:500. Following threewashing, the blots were incubated for 1 hwith horseradish
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binding was detected using enhanced chemiluminescence and quantified in an
Agfa Duoscan T1200 flatbed scanner using GeneTools software (Syngene, UK).
Whenever necessary, blots were stripped of primary and secondary antibodies by
incubation for 10 min at 70 °C in the stripping buffer (TBS containing 0.05%
Tween 20, 2% SDS and 1% 2-mercaptoethanol) [25,26] and reprobed.
2.8. Flow cytometry
Aliquots (45 μl) of washed platelets (1×108/ ml) were incubated at 37 °C for
1 min with 5 μl of FITC-PAC1 or FITC–annexin V, followed by treatment with
thrombin (1 U/ml) for the specified periods. Isotype-matched control antibodies
were used for FITC-PAC1 studies to rule out non-specific binding. Platelets were
fixed with 100 μl of 1% paraformaldehyde dissolved in PBS (pH 7.4). Flow
cytometrywas carried out with a FACSCalibur (BectonDickinson) flow cytometer
acquiring data at 10,000 events per sample. The geometric mean fluorescence
intensities in the stimulated and unstimulated samples were calculated.
2.9. Presentation of data
Data are presented as mean±S.E.M. of at least three individual experiments
from different blood donors. Analysis of statistical significance was performed
using Student's paired t-test and differences were considered significant when
p<0.05. Immunoblots shown are representatives of at least four different
experiments.3. Results
3.1. Dephosphorylation of specific proteins on tyrosine in
thrombin-stimulated platelets is regulated by extracellular
calcium and is independent of integrin αIIbβ3
Platelets were incubated with thrombin (1 U/ml) under non-
stirring condition for up to 45 min in the presence of 2 mM
extracellular Ca2+. Specific platelet proteins (of relative
mobilities 35, 67 and 75 kDa) were phosphorylated on tyrosine
following 2-min exposure to thrombin, which almost remained
unchanged until 30 min. This was followed by significant
dephosphorylation of these three proteins (by 39±3%, 32±2%
and 39±3%, respectively, compared to the cells activated for
2 min; p<0.05, for all the three proteins) after 45 min of
thrombin stimulation (Fig. 1A, left panel, and Fig 1B). To further
exclude the contribution of outside-in signaling we preincubated
the platelets with the tetrapeptide RGDS (0.5 mM), which
prevents binding of fibrinogen to the integrin. Presence of
RGDS did not alter the state of phosphorylation of these proteins
(data not shown), thus ruling out possible role of integrin-
mediated signaling inputs in the process of dephosphorylation.
In order to examine the role of Ca2+ in thrombin-induced
dephosphorylation, BAPTA-AM (50 μM) and EGTA (4 mM)
were used to chelate intracellular and extracellular Ca2+, res-
pectively. Presence of either EGTA alone, or EGTA combined
with BAPTA-AM, partially prevented dephosphorylation of the
specific proteins (Fig. 1A, right panel). The inhibition of
dephosphorylation after 45 min of thrombin stimulation was
reflected in an increase in the intensities of the 35, 67 and 75 kDa
bands by 4±1%, 20±1%and 17±5% (p<0.05, for 67 and 75 kDa
bands), respectively, in the EGTA-treated platelets and by 14±
1%, 37±4% and 23±5% (p<0.05, for all three bands), res-
pectively, in the cells treated together with EGTA and BAPTA,compared to the cells suspended in presence of calcium (Fig. 1C).
This was indicative of a regulatory role of calcium in the process
of dephosphorylation. Almost identical observations were made
when platelets were stimulated with thrombin receptor-activating
peptide (TRAP) (10 μM), another PAR agonist, but the extent of
dephosphorylation was found to be less (not shown).
3.2. Protein tyrosine dephosphorylation in thrombin-stimulated
platelets is associated with upregulation of SHP1
Total platelet PTP activity was estimated in the platelets
stimulated with thrombin in the absence of stirring. Resting
platelets were found to have significant level of basal PTP
activity, which was attenuated by preincubation with pervana-
date (1 mM), a non-specific phosphatase inhibitor (data not
shown). Stimulation with thrombin for 2 min led to an increase
in total phosphatase activity by 14±4% and 7±1%, respec-
tively, in the platelets incubated with calcium and EGTA (Fig.
2A). When cells were exposed to thrombin either for 30 min or
45 min in presence of calcium, total PTP activity was
increased by 17± 4% or 38±7% of basal activity, respectively.
On the contrary, there was lesser increase in PTP activity
beyond 2 min in the EGTA-treated platelets. PTP activity at
45 min was significantly lower in the presence of EGTA
compared to that in the Ca2+-treated platelets (p<0.05, Fig.
2A), implicating a role for extracellular Ca2+ in stimulation of
PTP. To correlate PTP activity with dephosphorylation of
specific platelet proteins, we studied the effect of phenylarsine
oxide (2 μM) on protein tyrosine phosphorylation. The extents
of phosphorylation of 35, 67, and 75 kDa peptides were found
to be higher (by 44±2%, 42±2% and 44±3%, respectively;
p<0.05, for all three bands) in the PAO-treated platelets
stimulated for 45 min in presence of calcium (Fig. 2B), com-
pared to those in the absence of PAO, implicating phos-
phatase activity with the observed dephosphorylation. Similar
observations were made with sodium orthovanadate (7.5 mM),
another pharmacologically independent inhibitor (data not
shown).
SHP1 is a major PTP expressed in the platelets, which is
activated in a Ca2+-dependent manner in thrombin-stimulated
cells [7,20]. To explore the role of SHP1, tyrosine phosphatase
assay was carried out in the presence of protein tyrosine
phosphatase inhibitor-1, a specific inhibitor of SHP1 [27] and
PTP1B, in the calcium-treated platelets stimulated with throm-
bin. In preliminary studies optimum conditions for the activity
of the inhibitor were determined. For the subsequent experi-
ments platelets were subjected to 5 min preincubation with
the inhibitor (50 μM), at which the enzymatic activity of the
immunoprecipitated SHP1 was completely inhibited. The SHP1
inhibitor reduced total tyrosine phosphatase activity in the
activated platelets at all the time points studied up to 45 min
(Fig. 3A). However, the decrease was not significant in the resting
platelets and in the cells stimulated for 2 min. The reduction in
total phosphatase activity by SHP1 inhibitor was statistically
significant when platelets were stimulated continuously for
30 min (p<0.05, n=5) or 45 min (p<0.01, n=5) with thrombin
(Fig. 3A). SHP1 inhibitor elicited an increase in the
Fig. 1. Tyrosine dephosphorylation of platelet proteins following sustained stimulation with thrombin. Effect of extra- and intracellular calcium. (A) Platelets were
activated with thrombin (1 U/ml) for different time intervals in the presence of Ca2+ (2 mM), EGTA (4 mM) or BAPTA-AM (50 μM) as indicated. Cells were lysed and
immunoblotted against phosphotyrosine. The lowest panel shows the Coomassie staining of corresponding actin bands in the membrane to indicate equal loading in
the lanes. The left and right panels represent two different experiments carried out on platelets from different individuals. Panels B and C represent densitometric
analysis of the intensities of three specific bands (relative to corresponding actin bands) in the left and right panels of panel A, respectively. Data are presented as
percent change in intensity of bands from the basal levels (mean±S.E.M, n=3).
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40±4 and 41±3%, respectively (p<0.05, for all three bands),
compared to those in its absence, in the platelets stimulated for
45 min (Fig. 3B). Thus, activation of SHP1 was temporally
induced in the platelets exposed to thrombin for at least 30min.As
the inhibitor did not completely reverse the phosphatase activity to
the basal level, PTPs other than SHP1 may also be implicated in
the observed dephosphorylation. Subsequently, SHP1 was
immunoprecipitated from platelets stimulated for different time
points in presence of Ca2+ and in vitro phosphatase assay was
carried out on the immune complex (Fig. 3C). The SHP1 activity
was found to rise from its basal level in the unstimulated cells by
about 8, 42 and 99%, respectively, following 2, 30 and 45 min of
platelet stimulation.
To determine the tentative time point at which SHP1 gets
activated in agonist-treated platelets, the phosphatase inhibitor
was added at varying time intervals following thrombin
stimulation, as indicated in the Fig. 4. Cells were lysed following45min of stimulation (Fig. 4, lanes 3–8). There was no change in
the phosphotyrosine profile of the proteins when the SHP1
inhibitor was added either in the beginning or after 25 min of
thrombin stimulation (lanes 4 and 5, respectively, Fig. 4).
However, when the inhibitor was added after 30, 35 or 40 min
following addition of thrombin, there was dephosphorylation of
specific proteins (lanes 6, 7 and 8, respectively, Fig. 4),
indicating prior activation of SHP1. Thus, activity of SHP1
was putatively upregulated between 25 and 30 min following
exposure of platelets to thrombin.
3.3. Activated SHP1 gets tyrosine phosphorylated and
associates with Src
Tyrosine phosphorylation of SHP1 by the Src kinase and
regulation of Src activity by dephosphorylation induced by
SHP1 are shown to be reciprocally regulated [28]. Since there
was upregulation of SHP1 activity between 25 and 30 min of
Fig. 3. Activity of SHP1 is upregulated in thrombin-stimulated platelets.
Platelets were preincubated with either SHP1 inhibitor or DMSO and stimulated
with thrombin for different time intervals. (A) Total platelet phosphatase activity
was determined, as described in the legend to Fig. 2. Values are mean±S.E.M
(n=5) (*p<0.05; **p<0.01). (B) Platelet proteins were immunoblotted against
phosphotyrosine. (C) SHP1 was immunoprecipitated from platelets stimulated
for different time points in presence of Ca2+. In vitro phosphatase assay was
carried out on the immune complex. The graph shows the percent increase in
SHP1 activity from its basal level in unstimulated cells.
Fig. 2. Stimulation of protein tyrosine phosphatase activity in thrombin-treated
platelets. (A) Platelets were stimulated with thrombin in presence of Ca2+ (2mM)
or EGTA(4 mM) without stirring. PTP activity in the cell lysates was measured
from the generation of p-nitrophenolate from pNPP as described. Results are
mean±S.E.M of five experiments (*p<0.05). (B) Washed platelets were
activated with thrombin (1 U/ml) for varying time points in presence of Ca2+
as indicated. PAO (2 μM) or DMSO was added 5 min before agonist. Cells were
lysed and immunoblotted against phosphotyrosine.
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SHP1 and its association with Src. SHP1 was found to be phos-
phorylated on tyrosine (Fig. 5A) and co-immunoprecipitated
with Src (Fig. 5B) following 30 and 45 min of thrombin
stimulation in calcium-pretreated platelets. However, the
amount of Src coprecipitated with SHP1 was about 3% of
total, suggesting association of a fraction of cellular Src with
SHP1. Immunoprecipitation of SHP1 in the platelets treated
either with EGTA (4 mM) or PP1 (20 μM), a specific inhibitor of
Src, prevented its association with Src (Fig. 5B) as well as
tyrosine phosphorylation of SHP1 (data not shown), while PP3
(20 μM), the inactive analogue of PP1, had no effect (not
shown), thus implicating a regulatory role for calcium and Src
activity in SHP1 activation.
3.4. Level of intracellular calcium in thrombin-stimulated
platelets is regulated by the presence of calcium in suspension
buffer
Since dephosphorylation of specific platelet proteins was a
function of extracellular calcium, we studied subsequently thechanges in cytosolic calcium, [Ca2+]i, in the Fura 2-loaded
platelets exposed to thrombin for 45 min. Cytosolic Ca2+ rose
from the resting level of 52±6 nM to 375±13 nM within 10 s of
thrombin stimulation in presence of 2 mM extracellular calcium
(n=5) (Fig. 6A). The amplitude of transient [Ca2+]i spike was less
(297±10 nM)when extracellular calciumwas chelated by EGTA,
to be followed by a significant decrease in the Ca2+ plateau (Fig.
6A). The initial rise in calciumwas mainly due to release from the
intracellular stores, whereas maintenance of the cytosolic Ca2+
plateau could be attributed to influx from the extracellular source
[18,29]. Levels of cytosolic Ca2+ following 30 and 45 min of
thrombin exposure in the presence of calcium (134±15 and 158±
Fig. 4. Determination of temporal activation of SHP1 in thrombin-stimulated
platelets. SHP1 inhibitor was added either 5 min before (lane 4) or 25, 30, 35 or
40 min after (lanes 5–8, respectively) the addition of thrombin. Platelets were
lysed following 2 min (lane 2) or 45 min (lanes 3–8) after exposure to thrombin.
Lane 1, resting platelets. Cell lysates were subjected to Western analysis and
probed with anti-phosphotyrosine antibody. This is a representative of five
experiments.
Fig. 6. Changes in cytosolic calcium in the platelets stimulated with thrombin for
different time intervals. Effect of extracellular calcium and EGTA. (A) Fura-2-
loaded platelets were stimulated with thrombin (1 U/ml) at 37 °C without stirring
either in presence of Ca2+ (tracing 1) or EGTA (tracing 2). Changes in [Ca2+]i
were monitored with time as described under Results section. Fluorescence data
were acquired as 340/380 ratio (emission 510 nm) as described under
Experimental procedures. (B) Changes in [Ca2+]i after 30 and 45 min of
thrombin stimulation. Values are mean±S.E.M (n=5) (*p<0.05).
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significantly higher compared to those under EGTA conditions
(119±18 and 93±8 nM at 30 and 45 min respectively) (Fig. 6B).
3.5. Downregulation of fibrinogen-binding affinity of integrin
αIIbβ3 following prolonged stimulation of platelets with
thrombin
In order to understand the functional implications of signaling
changes in platelets following sustained stimulation, extent of
binding of PAC1, an antibody directed against the activation-
specific epitope on integrin αIIbβ3, to platelets was studied under
the experimental conditions. FITC-PAC1 binding was maxi-Fig. 5. SHP1 is tyrosine phosphorylated and coprecipitated with Src in a calcium-dep
either calcium, EGTA or PP1 as indicated. SHP1 was immunoprecipitated and blott
second lanes in each panel represent washed platelet lysates (WP) and controls (IgGmum at 2 min, which was significantly attenuated following 30
and 45 min of exposure to thrombin, thus signifying down-
regulation of the fibrinogen-binding affinity in thrombin-treated
platelets (Fig. 7A). To further substantiate this, platelet aggre-
gation was induced by stirring the cells at 1200 rpm following 2,
30 and 45 min after thrombin addition. Aggregation wasendent manner. Platelets were stimulated with thrombin (1 U/ml) in presence of
ed against phosphotyrosine, Src or SHP1, as shown in the panels. The first and
-treated), respectively.
Fig. 7. Impairment of platelet functions following prolonged stimulation with thrombin. (A) Binding of FITC-PAC-1 to thrombin-stimulated platelets. Data are
expressed as mean±S.E.M (n=3). (B) Platelets were activated with thrombin (1 U/ml) without stirring. At different time points aggregation was induced by stirring the
cell suspension and increase in transmittance was recorded. The duration of activation without stirring was as follows: 2 min (tracings 2 and 4), 30 min (tracings 3 and
6) and 45 min (tracings 5 and 7). Studies were carried out either in presence of 2 mMCa2+ (tracings 2, 3 and 5) or 4 mMEGTA (tracing 4, 6 and 7). Tracing 1 represents
platelet aggregation in resting cells. Arrowhead indicates initiation of stirring. Data are representative of four different experiments. (C) Platelets were incubated with
thrombin for different time periods as indicated. Clot formation was induced by addition of autologous plasma and allowed to retract for 1 h. The photograph shows the
extents of retraction of fibrin clots under different conditions and is the representative of three different experiments.
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sence of Ca2+ and was completely obliterated after 45 min (Fig.
7B). In EGTA-treated platelets, the decrease in aggregation was
more pronounced.
Ability to retract fibrin clot, another function mediated by the
integrin αIIbβ3, was subsequently studied in the platelets
exposed to thrombin in the presence of extracellular calcium.
The extent of the retraction of the clots was recorded after 1 h of
clot formation. Retraction was found to be progressively
inhibited with the duration of exposure of the platelets to throm-
bin (Fig. 7C).
Calpain, the key protease activated during platelet aggrega-
tion [30] or storage [31], is responsible for proteolysis of several
signaling and cytoskeletal proteins. Calpain activity was studied
in the platelets stimulated with thrombin for 45 min in Co-
omassie-stained gels. No degradation of talin and filamin
[31,32] was observed under above condition (data not shown),
thus ruling out calpain activation. Externalization of PS to the
outer platelet membrane leaflet, an activation response leadingto generation of procoagulant surface [33], was subsequently
studied from the extent of annexin V–FITC binding to the
platelet membrane. The amount of PS on membrane outer
leaflet was found to rise significantly within 2 min of thrombin
stimulation in presence of calcium, which did not change
significantly when platelets were continued to be stimulated for
up to 45 min (data not shown). The data were suggestive of
maintenance of stable procoagulant surface on platelet mem-
brane during prolonged thrombin stimulation.
4. Discussion
In a physiological milieu of developing thrombus platelets
remain continuously exposed to the agonists, including
thrombin, released locally in the immediate microambience.
Thrombin transmits its signals by ligation to its specific recep-
tors, PAR-1 and PAR-4 [34] as well as to GpIb [35], leading to
events like phosphoinositide turnover, rise in intracellular
calcium, dramatic activation of several tyrosine and serine/
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ligands like fibrinogen. These intracellular changes take place
very fast, starting from a few seconds after exposure of platelets
to thrombin until up to 3–5 min. However, the late signaling
events invoked in the thrombin-treated platelets, which would
reflect the physiological changes in platelets in and around the
growing thrombus in vivo, have not received significant research
attention.
In the present study we have analyzed the temporal sequence
of specific cellular events in platelets following sustained
exposure to thrombin in presence of extracellular calcium. There
was progressive impairment in the integrin-mediated events like
clot retraction, stirring-induced platelet aggregation and fibrino-
gen-binding affinity of the integrin αIIbβ3. Calpain activity was
not induced in these cells, in contrast to the earlier observations
in aggregated platelets [30] or in the platelets aging in vitro [31].
As platelet activation is associated with upregulation of several
protein tyrosine kinases, we studied the phosphotyrosine profile
in thrombin-stimulated platelets in the presence of extracellular
calcium. Three specific peptides (of relative mobilities 35, 67
and 75 kDa) were significantly dephosphorylated between 30
and 45 min of thrombin stimulation, indicative of late activation
of putative tyrosine phosphatase(s). As aggregation was
prevented by lack of stirring or inclusion of RGDS in the
resuspension buffer, signaling inputs from the surface integrins
were ruled out. Stimulation of platelets for 45 min exhibited a
rise in total platelet PTP activity by about 40% compared to that
in the resting cells. Dephosphorylation of proteins was not
observedwhen cells were stimulated with collagen as the agonist
(our unpublished observations), thus implicating PAR-mediated
signaling in the dephosphorylation events.
To identify the candidate phosphatase(s) responsible for the
observed dephosphorylation, we investigated the role of SHP1,
the predominant PTP present in the platelets. Preincubation of
the platelets with an inhibitor of SHP1 reduced total platelet
phosphatase activity significantly following 30 and 45 min of
thrombin exposure and significantly increased the phosphotyr-
osine contents of 35, 67 and 75 kDa peptides. SHP1 activity was
enhanced from its basal level in the unstimulated cells by about
42 and 99%, respectively, following 30 and 45 min of platelet
stimulation, indicating a temporal upregulation of platelet SHP1
activity at a late stage following exposure to thrombin. The 7%
increase in SHP1 activity following stimulation of platelets for
2 min was not significant. From a time course experiment we
determined the SHP1 activity to be induced between 25 and
30 min after the addition of thrombin. Although our data
suggest a significant increase in SHP1 activity under the expe-
rimental condition, they do not rule out a possible contribution
from PTP1B or another tyrosine phosphatase in the observed
dephosphorylation.
To identify the factors regulating phosphatase activation we
studied the association of SHP1 with the non-receptor tyrosine
kinase, Src, in thrombin-treated platelets. The latter has been
shown to activate SHP1 by phosphorylating it on tyrosine resi-
dues [28,36]. SHP1, in turn, regulates Src activity by depho-
sphorylating it on Y-530 [28]. Thus, activities of SHP1 and Src
appear to be reciprocally regulated in the platelets. In our studySHP1 was found to be tyrosine phosphorylated after 30 min of
thrombin stimulation, the extent of which was still higher after
45 min, consistent with the previous reports that phosphorylated
SHP1 is enzymatically active [8,20,21]. Src co-immunoprecipi-
tated with the phosphorylated SHP1 at 30- and 45-min time
points in thrombin-activated platelets incubated in presence of
calcium. PP1 (a specific inhibitor of Src) prevented tyrosine
phosphorylation of SHP1 as well as its association with Src, thus
implicating activated Src in the regulation of SHP1 activity.
From our data it was evident that, calcium present in the
extracellular medium critically regulated tyrosine phosphatase
activity in the thrombin-stimulated platelets. Capacitative entry
of calcium from the extracellular milieu is responsible for the
maintenance of intracellular Ca2+ plateau (after the initial spike)
in the thrombin-treated platelets [18,29], although non-capaci-
tative influx of Ca2+ has also been described in the platelets [37].
Tyrosine phosphatases have been implicated in the capacitative
Ca2+ entry in platelets [18]. In the present study intracellular
Ca2+ plateau remained significantly lowered at all the time
points studied in the absence of calcium in suspension buffer.
This was associated with lack of significant rise in platelet PTP
activity. Tyrosine-specific dephosphorylation of the three pro-
teins was, too, partially prevented. Interestingly, chelation of
extracellular calcium precluded tyrosine phosphorylation SHP1
and its association with Src in the thrombin-treated platelets,
which contrasted with the observation in presence of calcium,
thus signifying a potential role of calcium in regulating SHP1
activation.
SHP1 has been proposed to play a constitutive role in
maintaining low levels of protein tyrosine phosphorylation
within hemopoietic cells including platelets, as evidenced from
the early death of mice lacking active SHP1 (motheaten pheno-
type) [13]. SHP1 has also been shown to exert an inhibitory
influence on cellular activation through its recruitment to
phosphorylated immunoreceptor tyrosine-based inhibitory
motifs (ITIMs) and dephosphorylation of key signaling proteins
in the activation cascade [7,38–40]. It is possible that SHP1
activity contributed towards functional impairment of platelets
following sustained stimulation with thrombin, as reported in
this study. SHP1 has also been functionally implicated in
integrin-mediated platelet responses like clot retraction [19] and
post-aggregation events [20,21]. However, SHP1 activation
reported in the present study was integrin-independent as cells
were not aggregated. Our data are consistent with the following
model: platelets are incorporated into the growing hemostatic
plug in vivo under a thrombogenic environment. Platelets
remaining free in close proximity are continuously exposed to
thrombin generated locally, leading to a sustained high
intracellular Ca2+ plateau. The latter has a critical role in
regulating activation of SHP1 at a temporally late stage (after
25–30 min under in vitro condition). Src activity appears to be
stimulated consequent to the rise in [Ca2+]i but upstream of
SHP1 activation. The implication of dephosphorylation of the
three specific peptides is not clear and the role of other putative
tyrosine phosphatases cannot be ruled out from the above data.
Functionally, platelets exposed to above situation exhibit
decreased aggregability, associated with reduced fibrinogen-
139R. Gupta et al. / Biochimica et Biophysica Acta 1773 (2007) 131–140binding affinity of integrin αIIbβ3. This would prevent incor-
poration of these platelets into the growing thrombus, which is
an integrin-mediated event, and thus restrict the size of the
thrombus. In parallel, steady PS exposure would ensure a pro-
coagulant surface [33], or mark these cells for subsequent
clearance by the macrophages [41].
During the process of thrombus formation the adjacent
platelets ensure contact-dependent signaling through integrin
αIIbβ3, Eph kinases/ephrins and CD40L/CD40, leading to
stabilization of plug [42–44]. The growth of platelet plug is
subsequently inhibited and restricted to the site of the vessel
injury. Nitric oxide, ADPase and prostacyclins secreted from
intact endothelium have all been implicated in confining the
size of platelet plug [2]. The cGMP-PKG pathway in vWF
and thrombin signaling through GPIb-IX, also induces a late
inhibitory response that limits the size of platelet aggregates
[45]. Thus, the signaling pathway described in the present
report would contribute further to restrict incorporation of
the free peripheral platelets into the thrombus, preventing
further growth of thrombus and confining it to the site of the
lesion.
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